Gliomab-H: Began a U.S. Phase I trial that is expected to last about six months.

Novopharm Biotech Inc. (VSE: NVO), Toronto, Ontario Product: Gliomab-H, human monoclonal antibody Indication: Cancer Status: Began a U.S. Phase I trial that is expected to last about six months. The t...